Vemurafenib plus cobimetinib

DRUG2 trials

Sponsors

Netherlands Working Group on Immunotherapy of Oncology, Canadian Cancer Trials Group

Conditions

Advanced Solid TumorsLymphoma, Non-HodgkinMetastatic MelanomaMultiple Myeloma

Phase 2

Vemurafenib Plus Cobimetinib in Metastatic Melanoma

TerminatedNCT02414750

Netherlands Working Group on Immunotherapy of OncologyMetastatic Melanoma

Start: 2014-12-31End: 2020-11-30Updated: 2022-11-30

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

RecruitingNCT03297606

Canadian Cancer Trials GroupAdvanced Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma

Start: 2018-03-23End: 2027-01-31Target: 720Updated: 2026-03-27

Related Papers

Metabolic parameters on baseline and early [<sup>18</sup>F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma.

2025-05-28

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

BMC Cancer2023-02-2223 citations

Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.

Journal of Clinical Oncology2019-05-201 citations

Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.

Journal of Clinical Oncology2019-01-291 citations

Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial.

Journal of Clinical Oncology2018-05-2018 citations

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

2017-09-1515 citations